XML 109 R92.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Unaudited Quarterly Results of Operations (Detail) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2021
Mar. 31, 2020
Mar. 31, 2019
Disclosure Unaudited Quarterly Financial Information [Abstract]                      
Revenue $ 241,246 $ 231,663 $ 209,764 $ 164,850 $ 206,658 $ 221,584 $ 204,974 $ 207,666 $ 847,522 $ 840,883 $ 769,432
Cost of revenue 46,078 41,110 38,736 35,983 39,369 39,996 34,867 37,073 161,907 151,305 129,567
Other operating expenses 132,364 119,202 109,692 94,801 109,237 111,329 109,925 109,868 456,058 440,359  
Other income (expense) 10,690 [1] 9,384 [1] 11,579 [1] 27,010 [1] (18,739) [1] 26,757 [1] (42,824) [1] 42,413 [1] 58,663 [1] 7,606 [1] 38,548
Income before income taxes 73,494 80,735 72,915 61,076 39,313 97,016 17,358 103,138 288,220 256,825 263,360
Income tax provision 16,638 [2] 18,867 [2] 10,702 [2] 16,488 [2] 7,515 [2] 27,799 [2] 4,287 [2] 14,215 [2] 62,695 [2] 53,816 [2] 4,344
Net income $ 56,856 $ 61,868 $ 62,213 $ 44,588 $ 31,798 $ 69,217 $ 13,071 $ 88,923 $ 225,525 $ 203,009 $ 259,016
Basic net income per share $ 1.26 $ 1.37 $ 1.38 $ 0.99 $ 0.71 $ 1.53 $ 0.29 $ 1.97 $ 5.00 $ 4.49 $ 5.77
Diluted net income per share $ 1.24 $ 1.35 $ 1.36 $ 0.98 $ 0.70 $ 1.51 $ 0.28 $ 1.93 $ 4.94 $ 4.43 $ 5.61
Income tax provision $ 16,638 [2] $ 18,867 [2] $ 10,702 [2] $ 16,488 [2] $ 7,515 [2] $ 27,799 [2] $ 4,287 [2] $ 14,215 [2] $ 62,695 [2] $ 53,816 [2] $ 4,344
[1]

In fiscal year 2019, the Company invested $25.0 million in medical device company Shockwave Medical. The fair value of this investment as of March 31, 2021 was $38.7 million. The Company recognized a pre-tax gain of $50.8 million for the year ended March 31, 2021 and a pre-tax loss of $0.5 million for the year ended March 31, 2020 in other income (expense), net.
[2] The income tax provision for the years ended March 31, 2021 and 2020 included excess tax benefits of $12.1 million and $14.8 million, respectively. These recognized excess tax benefits resulted from restricted stock units that vested or stock options that were exercised during the years ended March 31, 2021 and 2020.